Invivyd, Inc. announced Jane Henderson, the Company's Chief Financial & Business Officer, will cease serving as an executive officer, as well as the Company's principal financial officer and principal accounting officer, effective as of October 13, 2022, with her employment terminating on November 11, 2022. On October 11, 2022, the Board of Directors of the Company appointed Frederick W. Driscoll, age 71, as the Company's Interim Chief Financial Officer and designated him as the Company's principal financial officer and principal accounting officer, effective as of October 13, 2022. Mr. Driscoll most recently served as the Chief Financial Officer of Renovacor, Inc. from March 2022 until his resignation in June 2022.

Prior to Renovacor, Mr. Driscoll served as the Chief Financial Officer of Flexion Therapeutics, Inc. from May 2021 to November 2021. He served in the same capacity from 2013 until his retirement from the position in 2017, during which time he led Flexion's initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013.

From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc. Prior to that time, he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016.

He has been a member of the board of directors of Cellectar Biosciences, Inc. since April 2017, MEI Pharma, Inc. since February 2018 and Cue Biopharma, Inc. since June 2018. Mr. Driscoll earned a B.S. in accounting and finance from Bentley University.